더바이오메틱스

비상장

THE Biometics Inc.

강호창

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

더바이오메틱스

Business Reg. No. 2148728613 · CEO 강호창

I.Investment Overview

Target더바이오메틱스 (2148728613)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명더바이오메틱스
영문명THE Biometics Inc.
대표자강호창
사업자등록번호2148728613
법인등록번호1101112715162
설립일2003.02.13

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW0.820210.120223.92023520240.62025
영업이익100M KRW-0.52021-1.220222.220233.32024-0.92025
순이익100M KRW2.12021-6.52022-5.82023-4.220247.12025
Item20252024202320222021
자산총계243.6억원247.3억원248.2억원245.8억원249.2억원
부채총계198.5억원195.2억원191.8억원183.6억원180.6억원
자본총계45억원52.1억원56.4억원62.2억원68.7억원
매출액6,285만원5억원3.9억원525만원8,050만원
영업이익-8,594만원3.3억원2.2억원-1.2억원-4,989만원
순이익7.1억원-4.2억원-5.8억원-6.5억원2.1억원

VI.Financial Ratios

FY2025 basis

-136.74%

영업이익률

1,134.76%

순이익률

2.93%

ROA

15.84%

ROE

441.04%

부채비율

18.48%

자기자본비율

VII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

더바이오메틱스 투심보고서 | Alpha Lenz